14 Recruiting Studies Using Ceralasertib
Active clinical trials that use this intervention, sourced directly from the NIH registry.
Browse by conditionTrials Using Ceralasertib
Testing Olaparib and AZD6738 in IDH1 and IDH2 Mutant Tumors
📍 University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
Malignant Solid Neoplasm
View Study & Checklist ➔ATr Inhibitor in Combination With Olaparib/Durvalumab (MEDI4736) in Gynaecological Cancers With ARId1A Loss or no Loss
📍 The Ottawa Hospital Cancer Centre — Ottawa, Ontario
Gynaecological Cancers
View Study & Checklist ➔Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
📍 City of Hope Comprehensive Cancer Center — Duarte, California
Clear Cell Renal Cell Carcinoma
View Study & Checklist ➔Testing the Addition of AZD6738 (Ceralasertib) to Immunotherapy to Increase Time Without Cancer for Patients With Non-Small Cell Lung Cancer
📍 NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro — Jonesboro, Arkansas
Lung Non-Small Cell Carcinoma
View Study & Checklist ➔Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy
📍 Research Site — Duarte, California
Non-Small Cell Lung Cancer
View Study & Checklist ➔To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.
📍 Research Site — Birmingham, Alabama
Metastatic Triple Negative Breast Cancer
View Study & Checklist ➔Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
📍 Dana-Farber Cancer Institute — Boston, Massachusetts
Recurrent Fallopian Tube Carcinoma
View Study & Checklist ➔A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy
📍 Research Site — Mobile, Alabama
Advanced or Metastatic Non-Small Cell Lung Cancer
View Study & Checklist ➔Olaparib With Ceralasertib in Recurrent Osteosarcoma
📍 UCSF Benioff Children's Hospital; UCSF Pediatrics Hematology Oncology — San Francisco, California
Osteosarcoma
View Study & Checklist ➔Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer
📍 University of Illinois Medical Center — Chicago, Illinois
Extensive Stage Small Cell Lung Cancer
View Study & Checklist ➔Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
📍 UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care — Irvine, California
Advanced Breast Carcinoma
View Study & Checklist ➔A Study of Ceralasertib Monotherapy and Ceralasertib Plus Durvalumab in Patients With Melanoma and Resistance to PD-(L)1 Inhibition
📍 Research Site — Los Angeles, California
Melanoma
View Study & Checklist ➔Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer
📍 M D Anderson Cancer Center — Houston, Texas
Advanced Breast Carcinoma
View Study & Checklist ➔Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study
📍 Loma Linda University Medical Center — Loma Linda, California
Extensive Stage Lung Small Cell Carcinoma
View Study & Checklist ➔